Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH known ✓ | Q9Y2I1 | 3/20 | 0.95 |
| ▸ | BLM | P54132 | 4/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 8/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | HTR1A | P08908 | 2/20 | 0.95 |
| ▸ | HRH2 | P25021 | 2/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.95 |
| ▸ | CFB | P00751 | 3/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxonidine SCHEMBL1230620 | 1.00 | BLM (0.97) | BLMALOX15PMP22TDP1ADRA2C | |
| Moxonidine SCHEMBL1321306 | 0.99 | BLM (1.00) | BLMALOX15PMP22TDP1ADRA2C | |
| Moxonidine SCHEMBL49143 | 0.97 | ADRA2C (1.00) | BLMALOX15PMP22TDP1ADRA2C | |
| Moxonidine SCHEMBL8390103 | 0.97 | ADRA2C (1.00) | BLMALOX15PMP22TDP1ADRA2C | |
| Moxonidine SCHEMBL29363838 | 0.97 | ADRA2C (1.00) | BLMALOX15PMP22TDP1ADRA2C | |
| Moxonidine SCHEMBL5006894 | 0.90 | ADRA2C (0.86) | BLMALOX15PMP22TDP1ADRA2C | |
| Moxonidine SCHEMBL8007695 | 0.90 | ADRA2C (0.86) | BLMALOX15PMP22TDP1ADRA2C | |
| SCHEMBL2325739 | 0.87 | ADRA2C (0.81) | BLMALOX15PMP22TDP1ADRA2C | |
| Moxonidine SCHEMBL6514578 | 0.87 | ADRA2C (0.80) | BLMALOX15PMP22TDP1ADRA2C | |
| Moxonidine SCHEMBL8019736 | 0.87 | ADRA2C (0.80) | BLMALOX15PMP22TDP1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195523-A1 | ORGANIC MOLECULES FOR TREATING MYELIN PATHOLOGIES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2025-06-19 | — | — | US | disclosed |
| WO-2025079973-A1 | DAMAGED SKIN ORGANOID MODEL AND DRUG SCREENING METHOD USING SAME | 주식회사 강스템바이오텍 | 2025-04-17 | — | — | WO | disclosed |
| EP-4496574-A1 | ORGANIC MOLECULES FOR TREATING MYELIN PATHOLOGIES | ICM (Institut du Cerveau et de la Moelle Épinière) (FR) | 2025-01-29 | — | — | EP | disclosed |
| US-20240401058-A1 | METHOD OF REGULATING PULMONARY ARTERY VASCULAR REMODELING | UNIV INDIANA TRUSTEES (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2023180474-A1 | ORGANIC MOLECULES FOR TREATING MYELIN PATHOLOGIES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023069997-A1 | METHOD OF REGULATING PULMONARY ARTERY VASCULAR REMODELING | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240401058-A1 | METHOD OF REGULATING PULMONARY ARTERY VASCULAR REMODELING | SPHK2, SPHK1, S1PR2 | NISCH 4070/4885BLM 3411/4885ALOX15 1669/4885 |
| US-20250195523-A1 | ORGANIC MOLECULES FOR TREATING MYELIN PATHOLOGIES | PMP22, MAG, MYT1 | NISCH 3579/4885BLM 4758/4885ALOX15 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.